DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: CRISPR/Cas9 editing approaches were also used to correct DMD exon mutations of increasing complexity animal models, including mice [24], dogs [43], pigs [44], etc. All these experiments support the idea that, these models are suitable for screening novel DMD gene-targeting therapies and, following further development for improved safety, gene-editing tools, in particular, may be applied to treat dystrophinopathy patients and ameliorate their quality of life.